| Original language | English |
|---|---|
| Pages (from-to) | 463-465 |
| Number of pages | 3 |
| Journal | Gastroenterology |
| Volume | 158 |
| Issue number | 3 |
| DOIs | |
| State | Published - Feb 2020 |
Access to Document
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Gastroenterology, Vol. 158, No. 3, 02.2020, p. 463-465.
Research output: Contribution to journal › Editorial
TY - JOUR
T1 - New Blood Marker of Endoscopic Disease Activity—A Step Forward in Treating Crohn's Disease to Target?
AU - Agrawal, Manasi
AU - Ungaro, Ryan C.
AU - Colombel, Jean Frederic
N1 - Funding Information: Conflicts of interest The authors have made the following disclosures: MA receives intramural research support from the Dickler Family Fund. RCU has served as a consultant and/or advisory board member for Eli Lilly, Janssen, Pfizer and Takeda. He has received research support from AbbVie , Boehringer Ingelheim and Pfizer . He is supported by Career Development Awards from the Crohn's and Colitis Foundation and the National Institutes of Health ( K23KD111995-01A1 ). JFC reports receiving research grants from AbbVie, Janssen Pharmaceuticals and Takeda; receiving payment for lectures from AbbVie, Amgen, Allergan, Inc. Ferring Pharmaceuticals, Shire, and Takeda; receiving consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Celgene Corporation, Celltrion, Eli Lilly, Enterome, Ferring Pharmaceuticals, Genentech, Janssen Pharmaceuticals, Landos, Ipsen, Medimmune, Merck, Novartis, Pfizer, Shire, Takeda, Tigenix, Viela bio; and hold stock options in Intestinal Biotech Development and Genfit. The PREDICT consortium to study preclinical biomarkers associated with IBD, led by Dr Colombel, is supported in part by Prometheus Laboratories Inc., San Diego, California. Funding Information: Conflicts of interest The authors have made the following disclosures: MA receives intramural research support from the Dickler Family Fund. RCU has served as a consultant and/or advisory board member for Eli Lilly, Janssen, Pfizer and Takeda. He has received research support from AbbVie, Boehringer Ingelheim and Pfizer. He is supported by Career Development Awards from the Crohn's and Colitis Foundation and the National Institutes of Health (K23KD111995-01A1). JFC reports receiving research grants from AbbVie, Janssen Pharmaceuticals and Takeda; receiving payment for lectures from AbbVie, Amgen, Allergan, Inc. Ferring Pharmaceuticals, Shire, and Takeda; receiving consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Celgene Corporation, Celltrion, Eli Lilly, Enterome, Ferring Pharmaceuticals, Genentech, Janssen Pharmaceuticals, Landos, Ipsen, Medimmune, Merck, Novartis, Pfizer, Shire, Takeda, Tigenix, Viela bio; and hold stock options in Intestinal Biotech Development and Genfit. The PREDICT consortium to study preclinical biomarkers associated with IBD, led by Dr Colombel, is supported in part by Prometheus Laboratories Inc., San Diego, California.
PY - 2020/2
Y1 - 2020/2
UR - http://www.scopus.com/inward/record.url?scp=85078842682&partnerID=8YFLogxK
U2 - 10.1053/j.gastro.2019.12.015
DO - 10.1053/j.gastro.2019.12.015
M3 - Editorial
C2 - 31866244
AN - SCOPUS:85078842682
SN - 0016-5085
VL - 158
SP - 463
EP - 465
JO - Gastroenterology
JF - Gastroenterology
IS - 3
ER -